by Maryline Bonnet, Nilesh Bhatt, Elisabeth Baudin et al.
The Lancet Infectious Diseases, Vol. 13, Issue 4, pp. 303-312, April 2013
In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. The authors aimed to compare efficacy and safety of a nevirapine-based antiretroviral therapy (started at full dose) with an efavirenz-based regimen in co-infected patients. They conclude that although non-inferiority of the nevirapine-regimen was not shown, nevirapine at full dose could be a safe, acceptable alternative for patients unable to tolerate efavirenz.